Helix BioPharma Corp. (HBP) - Cash Flow Conversion Efficiency

Latest as of January 2026: -0.030x

Based on the latest financial reports, Helix BioPharma Corp. (HBP) has a cash flow conversion efficiency ratio of -0.030x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-456.00K ≈ $-329.86K USD) by net assets (CA$15.36 Million ≈ $11.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HBP equity financing ratio to measure how much of total assets are equity-financed.

Helix BioPharma Corp. - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Helix BioPharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Helix BioPharma Corp. strategic investment ratio to see how much of total assets are deployed in long-term investments.

Helix BioPharma Corp. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Helix BioPharma Corp. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Pureun Mutual Savings Bank Co. Ltd KQ:007330	-0.031x
NoiBai Cargo Terminal Services JSC VN:NCT	0.042x
Orthex Oyj HE:ORTHEX	0.158x
Kyongbo Pharmaceutical Co Ltd KO:214390	0.031x
Shenzhen Nanshan Power Co Ltd SHE:200037	-0.035x
Coloray International Investment Co. Ltd KQ:900310	0.003x
Geodrill Limited TO:GEO	-0.009x
OSE Pharma SA PA:OSE	-0.355x

Annual Cash Flow Conversion Efficiency for Helix BioPharma Corp. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Helix BioPharma Corp. from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Helix BioPharma Corp. market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-07-31	CA$15.59 Million ≈ $11.27 Million	CA$-3.83 Million ≈ $-2.77 Million	-0.246x	-100.42%
2024-07-31	CA$-90.00K ≈ $-65.10K	CA$-5.22 Million ≈ $-3.78 Million	57.989x	+785.52%
2023-07-31	CA$-844.00K ≈ $-610.54K	CA$-5.53 Million ≈ $-4.00 Million	6.549x	+132.09%
2022-07-31	CA$319.00K ≈ $230.76K	CA$-6.51 Million ≈ $-4.71 Million	-20.404x	-405.50%
2021-07-31	CA$-1.39 Million ≈ $-1.01 Million	CA$-9.30 Million ≈ $-6.73 Million	6.679x	+283.91%
2020-07-31	CA$2.98 Million ≈ $2.16 Million	CA$-10.83 Million ≈ $-7.83 Million	-3.632x	-315.43%
2019-07-31	CA$-3.28 Million ≈ $-2.37 Million	CA$-5.53 Million ≈ $-4.00 Million	1.686x	-65.79%
2018-07-31	CA$-1.53 Million ≈ $-1.10 Million	CA$-7.52 Million ≈ $-5.44 Million	4.927x	-99.10%
2017-07-31	CA$-17.00K ≈ $-12.30K	CA$-9.29 Million ≈ $-6.72 Million	546.765x	+19640.99%
2016-07-31	CA$3.16 Million ≈ $2.29 Million	CA$-8.85 Million ≈ $-6.40 Million	-2.798x	-125.05%
2015-07-31	CA$6.83 Million ≈ $4.94 Million	CA$-8.49 Million ≈ $-6.14 Million	-1.243x	-10.09%
2014-07-31	CA$6.81 Million ≈ $4.93 Million	CA$-7.69 Million ≈ $-5.56 Million	-1.129x	+28.89%
2013-07-31	CA$4.92 Million ≈ $3.56 Million	CA$-7.81 Million ≈ $-5.65 Million	-1.588x	+29.95%
2012-07-31	CA$6.22 Million ≈ $4.50 Million	CA$-14.11 Million ≈ $-10.21 Million	-2.267x	-384.94%
2011-07-31	CA$22.11 Million ≈ $16.00 Million	CA$-10.34 Million ≈ $-7.48 Million	-0.468x	+39.56%
2010-07-31	CA$15.76 Million ≈ $11.40 Million	CA$-12.19 Million ≈ $-8.82 Million	-0.774x	-0.33%
2009-07-31	CA$17.06 Million ≈ $12.34 Million	CA$-13.16 Million ≈ $-9.52 Million	-0.771x	-126.16%
2008-07-31	CA$20.52 Million ≈ $14.85 Million	CA$-7.00 Million ≈ $-5.06 Million	-0.341x	+28.58%
2007-07-31	CA$12.73 Million ≈ $9.21 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.477x	--

About Helix BioPharma Corp.

TO:HBP Canada Biotechnology

Market Cap

$82.88 Million

CA$114.57 Million CAD

Market Cap Rank

#19815 Global

#669 in Canada

Share Price

CA$1.50

Change (1 day)

+0.00%

52-Week Range

CA$0.98 - CA$5.31

All Time High

CA$11.25